Angiogenesis, Exudation, and Degeneration 2020

February 8, 2020

Bascom Palmer Eye Institute invites you to join us in February 2020 for our seventeenth annual angiogenesis meeting. This unique and exciting symposium entitled Angiogenesis, Exudation, and Degeneration 2020 will be held February 8, 2020 at the Mandarin Oriental Hotel in Miami, Florida. The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
DATE
Saturday, February 8, 2020

LOCATION
Mandarin Oriental Miami
500 Brickell Key Drive
Miami, FL 33131

COURSE CO-DIRECTORS
Philip J. Rosenfeld, MD, PhD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

Harry W. Flynn, Jr., MD
Professor of Ophthalmology
J. Donald M. Gass Distinguished Chair in Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

Thomas A. Albini, MD
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

COURSE DESCRIPTION
Angiogenesis 2020 follows the tradition of excellence established by Bascom Palmer’s widely acclaimed Angiogenesis programs between 2004 and 2019. Designed for retina specialists, general ophthalmologists and researchers, the current program will review the latest in translational research and clinical trials with an emphasis on how these results will impact clinical ophthalmology. We will emphasize early phase clinical trials and recently completed studies focused on the treatment of a wide range of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and retinal degenerations.

COURSE OBJECTIVES
Upon completion of this program, participants should be able to:
• Examine new evidence regarding the current global use of anti-VEGF drugs for exudative ocular diseases
• Evaluate risks associated with injections of anti-VEGF drugs
• Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
• Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice
• Evaluate the benefits and limitations of combination therapies for macular diseases
• Evaluate the benefits and limitations of different imaging strategies for macular diseases
• Provide patients with information on the genetic nature and genetic transmission of the disease and its implication for other family members.
• Use OCT to diagnose and manage macular and retinal diseases
• Evaluate the emerging imaging technology known as OCT angiography and how this technology might improve the diagnosis of macular and retinal diseases, as well as the clinical management of patients with these diseases
SATURDAY, FEBRUARY 8, 2020

7:00 am  Registration and Continental Breakfast
7:50  Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD

SESSION I: Aging, Disease Pathogenesis, and Imaging
Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA

8:00  Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration
Philip Luthert, MBBS

8:08  Ultrahigh Speed OCTA for Assessing Choriocapillaris Flow Impairment
James G. Fujimoto, PhD

8:16  Challenges in Imaging the Choriocapillaris
Richard F. Spaide, MD

8:24  Choriocapillaris Quantification with Phansalkar’s Local Thresholding: Do’s and Don’ts
Zhongdi Chu, PhD

8:32  Choriocapillaris in Myopia
SriniVas R. Sadda, MD

8:40  Choroidal Vessel Imaging and Quantification
Ruikang (Ricky) Wang, PhD

8:48  The Choroid in AMD: Connecting the Dots
Philip J. Rosenfeld, MD, PhD

8:56  Deep Learning and Reticular Pseudodrusen
Emily Y. Chew, MD

SESSION II: Retinal Diseases and Functional Endpoints
Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD

9:04  MacTel2 as a “Serine/Ceramide-Opathy”
Martin Friedlander, MD, PhD

9:12  Epidemiology of Common Retinal Diseases in Retina Practices in the United States
Andrew A. Moshfeghi, MD, MBA

9:20  Functional Imaging of Mitochondria in Retinal Diseases
Rishi P. Singh, MD

9:28  Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes
Usha Chakravarthy, MD

9:36  Drusen and Retinal Diseases
Lawrence A. Yannuzzi, MD

9:44  Integrating Micropereimetry into Clinical Trials of Nonexudative AMD
Nadia Waheed, MD

9:52  Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials?
Christine A. Curcio, PhD

10:00 Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD
Karl G. Csaky, MD, PhD
SESSION III: AMD II
Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD

10:08 Retina Trends – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

10:16 Update in Hemera’s Gene Therapy Programs
Jay S. Duker, MD

10:24 Kamuvudines for AMD: The Saga Continues
Jayakrishna Ambati, MD

10:32 Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy
Sunil S. Patel, MD, PhD

10:40 Update on FHTR2163 (anti-HtrA1) for Dry AMD
Vrinda Hershberger, MD, PhD

10:48 Update on Elamipretide for the Treatment of AMD
Scott W. Cousins, MD

10:56 Phase 2 Study Results of Risuteganib in Dry AMD
Peter K. Kaiser, MD

11:04 Risuteganib for the Treatment of Dry AMD: Structure/Function Correlations
Glenn J. Jaffe, MD

11:12 Update on Brimonidine Intravitreal Implant for Dry AMD
Ryan Rich, MD

11:20 C3 inhibition in Geographic Atrophy
Cedric G. Francois, MD, PhD

SESSION IV: AMD III
Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD

11:28 PROCON Year 2 Results
Jeffrey S. Heier, MD

11:36 Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader
David Sarraf, MD

11:44 Update on Stem Cell Therapies for AMD
Amir H. Kashani, MD, PhD

11:52 Unregulated Stem Cells for Ocular Disease: What Happened after the NEJM Publication
Thomas A. Albini, MD

12:00 pm Retinal Implants: Where Are We Now?
Jean-François Korobelnik, MD

12:08 Advanced Retinal Implants
Mark S. Humayun, MD, PhD

12:16 Lunch

SESSION IV: Macular Neovascularization in AMD and PCV
Moderators: Philip J. Rosenfeld, MD, PhD and Luis J. Haddock, MD

1:16 The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials
Giovanni Staurenghi, MD

1:24 Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning
Aaron Y. Lee, MD

1:32 AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device
Anat Loewenstein, MD
1:40 Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA
Luis de Sisternes, PhD
1:48 Rotational 3D OCTA
Giuseppe Querques, MD, PhD
1:56 Diagnosis of PCV Using SS-OCTA
Hiroko Terasaki, MD, PhD
2:04 Volume Rendering of OCTA in PCV
K. Bailey Freund, MD
2:12 A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA
Seung-Young Yu, MD
2:20 Longitudinal Changes in Subclinical PCV
Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI
2:28 Longitudinal Observations of PCV Using SS-OCTA
Fenghua Wang, MD

SESSION VI: Treatments for Neovascularization in AMD and ROP
Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD

2:36 Immunology of Gene Therapy
Janet L. Davis, MD
2:44 Phase 1 study of Intravitreal Gene Therapy with DVM-022 for Neovascular AMD (OPTIC Trial)
David S. Boyer, MD
2:52 RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy
Jeffrey S. Heier, MD
3:00 Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290
Michael W. Stewart, MD
3:08 Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD
Quan Dong Nguyen, MD, MSc
3:16 Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD
Diana V. Do, MD
3:24 Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD
Pravin U. Dugel, MD
3:32 Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results
Carl D. Regillo, MD
3:40 Farcimab Update
Karl G. Csaky, MD, PhD
3:48 Brolucizumab Update
Lawrence J. Singerman, MD
3:56 Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept
David M. Brown, MD
4:04 Update on ROP and Anti-VEGF Clinical Trials
Darius M. Moshfeghi, MD
SESSION VII: Diabetes
Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD

4:12 Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease
Jayanth Sridhar, MD

4:20 DRCR Retina Network Trials and Real World Experience
Jennifer Sun, MD

4:28 Diabetic Retinopathy: Is a New Classification on the Way?
Lee M. Jampol, MD

4:36 Artificial Intelligence Assisted Approaches for Diabetic Retinopathy Screening
Michael S. Ip, MD

4:44 The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA
Ramin Tadayoni, MD, PhD

4:52 Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy
Toshinori Murata, MD, PhD

5:00 Widefield SS-OCTA in Diabetic Retinopathy
Harry W. Flynn, Jr. MD

5:08 Development of DME in Fellow Eyes from VIVID/VISTA
Dilsher Dhoot, MD

5:16 Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study
Charles C. Wykoff, MD, PhD

SESSION VIII: Diabetes, Uveitis, and Retinal Degenerations
Moderators: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD

5:24 A Novel Implant for Delivering Low-Dose Extended Release Dexamethasone for Macular Edema
Elias Reichel, MD

5:32 The Oculis OCS-01 Phase 1/2 Study: An Effective Topical Therapeutic for DME
Pravin U. Dugel, MD

5:40 Front-line Local Therapies for Uveitis: From Clinical Trials to Practice
Steven Yeh, MD

5:48 Treatments and Clinical Trials in Inherited Retinal Degenerations
Byron L. Lam, MD

5:56 Phase 2 1-year Results of the JCyte Trial for Retinitis Pigmentosa
David S. Boyer, MD

6:04 Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa
Peter A. Campochiaro, MD

6:12 Post-Program Test and Closing Remarks

6:20 Adjourn/Cocktail Reception
BASCOM PALMER EYE INSTITUTE
Angiogenesis, Exudation, and Degeneration 2020

Mandarin Oriental Miami
500 Brickell Key Drive
Miami, FL 33131
Reservations: (800) 526-6566
Direct: (305) 913-8288

Mandarin Oriental Miami is one of America’s finest hotels and recently voted Best Urban Hotel by Miami Herald’s Readers Choice South Florida’s Finest survey-Best of South Florida. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly befits the opulence you’ll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel’s extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

HOTEL RESERVATIONS
For hotel information and reservations, please call 305-913-8288 or 800-526-6566.

The special hotel rate for conference attendees is $439 per night for single or double plus tax. The Mandarin Oriental will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

We suggest you make your hotel reservations as soon as possible as the winter months are the height of South Florida’s tourist season. Bascom Palmer’s preferred room rate will be released after January 9, 2020. Reservations and deposits received after that time are subject to current rates and availability. Please contact the Mandarin Oriental Miami for hotel cancellation policies. For additional information visit: www.mandarinoriental.com/miami

CONFERENCE FEES
Registration rate is $475.
Conference fees include course materials, opening reception, continental breakfast, lunch and refreshment breaks.

CANCELLATION POLICY
Conference tuition, less a $50 cancellation fee, is refundable if notice is received by January 24, 2020. No refunds shall be considered after January 24, 2020 or after sixty (60) days following payment.
TARGET AUDIENCE:
Physicians (retina specialists and general ophthalmologists) and researchers

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

REGISTRATION
Space is limited. Please register early.

To register by internet: Please visit:
http://bascompalmer.org/cme/angiogenesis/registration

To register by mail: Please complete the registration form and return with your check or credit card payment to:
Bascom Palmer Eye Institute
Department of Continuing Medical Education
900 NW 17th Street, Suite 6
Miami, FL 33136 (Att: Karen Davila)

To register by fax: Please complete the registration form and return with your credit card payment to (305) 326-6518.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 24, 2020.

FOR MORE INFORMATION
Bascom Palmer Eye Institute
Department of Continuing Medical Education at
(305) 326-6110 / Email: bascompalmercme@miami.edu

www.bascompalmer.org
Registration Form

BASCOM PALMER EYE INSTITUTE

Angiogenesis, Exudation, and Degeneration 2020

February 8, 2020
Registration is limited, so please register early.

/ 
Last Name / First Name (as you want it to appear on name badge) 
/ 
Birth month/day (MM/DD) (for record keeping purposes only) Degree(s)

Specialty / Sub-specialty

Affiliated Institution

Address (Check box if new address)

City/State

Country / Zip or Postal Code

Office phone Office fax

Email (Required)

REGISTRATION: $475

☐ Enclosed is my check made payable to Bascom Palmer Eye Institute – Angiogenesis 2020

☐ Please bill my credit card:
  ☐ Mastercard ☐ Visa ☐ American Express

Card number

Security code Expiration date Billing zip code

Name on card

Signature

Online: bascompalmer.org/cme/angiogenesis/registration
By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518.
By mail: Please complete this registration form and return with your check or credit card payment to: Bascom Palmer Eye Institute Continuing Medical Education Department 900 NW 17th Street, Suite 6 Miami, FL 33136 (Attn: Karen Davila)
By e-mail: bascompalmercme@miami.edu